Evelien Schaafsma
Research Subjects
Evelien Schaafsma has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Chao Cheng
Department of Medicine, Baylor College of Medicine, Houston, TX, USA
24 shared publications - Aurelien Sarde
Department of Microbiology and Immunology, Dartmouth Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire
18 shared publications - Cecilia A. Webber
College of Arts & Sciences, Boston University, Boston, Massachusetts
18 shared publications - Dina Rabadi
Department of Biological Sciences, Dartmouth College, Hanover, New Hampshire
18 shared publications - Elizabeth C. Nowak
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA
18 shared publications - Janet Louise Lines
Dartmouth College
18 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Quality control and cluster identification of CD45-enriched scRNAseq data. In the I/V model, BALB/c mice were administered 100k CT26 cells and treated when tumors reached a size of 40mm3 with isotype (I) or anti-VISTA (V). In the CPV model, BALB/c mice were administered 100k CT26 cells and treated with anti-CTLA-4 and anti-PD-1 plus isotype (CP) or plus anti-VISTA (CPV) when tumors reached a size of 600mm3. In both models, CD45+ cells were isolated from the TME and analyzed by scRNAseq. (A) Histogram of the number of reads (left) and the number of genes (right) detected in all cells within the I/V dataset. (B) Histogram of the number of reads (left) and the number of genes (right) detected in all cells within the CP/CPV dataset. (C) Visual representation of lymphoid and myeloid cell distributions between experimental replicates using UMAP plots. (D) Expected and observed Local Inverse Simpson’s Index (LISI) measuring the degree of mixing among datasets. The LISI score ranges from 1 in an unmixed space to 2 in a perfectly mixed space with equal numbers of cells in each dataset. (E) AUCs calculated based on fivefold cross-validation where cells from each cluster are split into training and test datasets, a logistic regression classifier is trained on the training dataset and applied to the test dataset to measure model accuracy for each cluster. Higher AUC values correspond to better cluster discrimination. (F) Comparison of the number of cells detected per cluster in the I/V and CP/CPV datasets. (G) Comparison of the number of genes detected per cluster. (H) UMAP of all CD45+ cells sorted from I/V- and CP/CPV-treated tumor infiltrates, colored by cell cluster based on Louvain clustering. (I) Dot plots of cluster-defining marker genes for cell type annotations (as in H). Dot size represents fraction of cells expressing a gene in each cluster. Dot color represents scaled average expression by gene column.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Quality control and cluster identification of CD45-enriched scRNAseq data. In the I/V model, BALB/c mice were administered 100k CT26 cells and treated when tumors reached a size of 40mm3 with isotype (I) or anti-VISTA (V). In the CPV model, BALB/c mice were administered 100k CT26 cells and treated with anti-CTLA-4 and anti-PD-1 plus isotype (CP) or plus anti-VISTA (CPV) when tumors reached a size of 600mm3. In both models, CD45+ cells were isolated from the TME and analyzed by scRNAseq. (A) Histogram of the number of reads (left) and the number of genes (right) detected in all cells within the I/V dataset. (B) Histogram of the number of reads (left) and the number of genes (right) detected in all cells within the CP/CPV dataset. (C) Visual representation of lymphoid and myeloid cell distributions between experimental replicates using UMAP plots. (D) Expected and observed Local Inverse Simpson’s Index (LISI) measuring the degree of mixing among datasets. The LISI score ranges from 1 in an unmixed space to 2 in a perfectly mixed space with equal numbers of cells in each dataset. (E) AUCs calculated based on fivefold cross-validation where cells from each cluster are split into training and test datasets, a logistic regression classifier is trained on the training dataset and applied to the test dataset to measure model accuracy for each cluster. Higher AUC values correspond to better cluster discrimination. (F) Comparison of the number of cells detected per cluster in the I/V and CP/CPV datasets. (G) Comparison of the number of genes detected per cluster. (H) UMAP of all CD45+ cells sorted from I/V- and CP/CPV-treated tumor infiltrates, colored by cell cluster based on Louvain clustering. (I) Dot plots of cluster-defining marker genes for cell type annotations (as in H). Dot size represents fraction of cells expressing a gene in each cluster. Dot color represents scaled average expression by gene column.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Additional data supporting Figure 3. (A) Pathway enrichment for each cluster described in figure 3. (B) Comparison of myeloid clusters from this study with those identified by [30]. Dots represent the proportion of myeloid clusters described in this study (bottom) in the Gubin et al. myeloid clusters (left). Each row is normalized by row sums. Cluster identity from [30] was obtained from the original publication. (C) Cluster frequencies as a proportion of the myeloid infiltrate in I/V or CP/CPV treatment.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Additional data supporting Figure 3. (A) Pathway enrichment for each cluster described in figure 3. (B) Comparison of myeloid clusters from this study with those identified by [30]. Dots represent the proportion of myeloid clusters described in this study (bottom) in the Gubin et al. myeloid clusters (left). Each row is normalized by row sums. Cluster identity from [30] was obtained from the original publication. (C) Cluster frequencies as a proportion of the myeloid infiltrate in I/V or CP/CPV treatment.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Supplementary Figure S3. Anti-VISTA-induced changes to tumor-infiltrating immune cells in MB49. B6 mice were injected intra-dermally with 100k MB49 cells and treated when tumors reached a size of 100mm3 with isotype (I) or anti-VISTA (V). (A) Macrophage to monocyte ratio as determined by flow cytometry (B) Macrophage (CD45+, CD11b+, Gr1-, F4/80hi) frequency per gram of tumor as determined by flow cytometry. Expression of iNOS (C), MHC-II (D), and CD40 (E), was determined on CD45+, CD11b+, Gr1-, F4/80+ macrophages by flow cytometry. (F) CD40 expression within granulocytes (CD45+, CD11b+, Ly6G+, F4/80-) as determined by flow cytometry. Data are represented as mean ± SD. *P < 0.05.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Supplementary Figure S3. Anti-VISTA-induced changes to tumor-infiltrating immune cells in MB49. B6 mice were injected intra-dermally with 100k MB49 cells and treated when tumors reached a size of 100mm3 with isotype (I) or anti-VISTA (V). (A) Macrophage to monocyte ratio as determined by flow cytometry (B) Macrophage (CD45+, CD11b+, Gr1-, F4/80hi) frequency per gram of tumor as determined by flow cytometry. Expression of iNOS (C), MHC-II (D), and CD40 (E), was determined on CD45+, CD11b+, Gr1-, F4/80+ macrophages by flow cytometry. (F) CD40 expression within granulocytes (CD45+, CD11b+, Ly6G+, F4/80-) as determined by flow cytometry. Data are represented as mean ± SD. *P < 0.05.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Supplementary Figure S4. Additional data supporting Figure 6. In the I/V model, BALB/c mice were administered 100k CT26 cells and treated when tumors reached a size of 40mm3 with isotype (I) or anti-VISTA (V). In the CPV model, BALB/c mice were administered 100k CT26 cells and treated with anti-CTLA-4 and anti-PD-1 plus isotype (CP) or plus anti-VISTA (CPV) when tumors reached a size of 600mm3. CD45 + (A-C, E) or CD8+ AH1-tetramer+ (D) cells were isolated from the TME and analyzed by scRNAseq. (A) Stacked bar graph showing all lymphoid cluster frequencies as a proportion of the lymphoid infiltrate for I/V and CP/CPV. (B) Stacked bar graph showing NK cluster frequencies as a proportion of the NK infiltrate for I/V and CP/CPV. (C) Stacked bar graph showing CD8+ T cell cluster frequencies as a proportion of the CD8+ T cell infiltrate for I/V and CP/CPV. (D) Mean cluster frequencies as a proportion of CD8+ AH1-tetramer+ T cells in I/V or CP/CPV treatment. (E) Violin plots showing enrichment of a quiescence gene signature in CD8+ T cell clusters in the CD45 + sorted I/V dataset[58]. *P < 0.05, **P < 0.01, ***P < 0.001.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Supplementary Figure S4. Additional data supporting Figure 6. In the I/V model, BALB/c mice were administered 100k CT26 cells and treated when tumors reached a size of 40mm3 with isotype (I) or anti-VISTA (V). In the CPV model, BALB/c mice were administered 100k CT26 cells and treated with anti-CTLA-4 and anti-PD-1 plus isotype (CP) or plus anti-VISTA (CPV) when tumors reached a size of 600mm3. CD45 + (A-C, E) or CD8+ AH1-tetramer+ (D) cells were isolated from the TME and analyzed by scRNAseq. (A) Stacked bar graph showing all lymphoid cluster frequencies as a proportion of the lymphoid infiltrate for I/V and CP/CPV. (B) Stacked bar graph showing NK cluster frequencies as a proportion of the NK infiltrate for I/V and CP/CPV. (C) Stacked bar graph showing CD8+ T cell cluster frequencies as a proportion of the CD8+ T cell infiltrate for I/V and CP/CPV. (D) Mean cluster frequencies as a proportion of CD8+ AH1-tetramer+ T cells in I/V or CP/CPV treatment. (E) Violin plots showing enrichment of a quiescence gene signature in CD8+ T cell clusters in the CD45 + sorted I/V dataset[58]. *P < 0.05, **P < 0.01, ***P < 0.001.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Quality control and cluster identification of CD45-enriched scRNAseq data. In the I/V model, BALB/c mice were administered 100k CT26 cells and treated when tumors reached a size of 40mm3 with isotype (I) or anti-VISTA (V). In the CPV model, BALB/c mice were administered 100k CT26 cells and treated with anti-CTLA-4 and anti-PD-1 plus isotype (CP) or plus anti-VISTA (CPV) when tumors reached a size of 600mm3. In both models, CD45+ cells were isolated from the TME and analyzed by scRNAseq. (A) Histogram of the number of reads (left) and the number of genes (right) detected in all cells within the I/V dataset. (B) Histogram of the number of reads (left) and the number of genes (right) detected in all cells within the CP/CPV dataset. (C) Visual representation of lymphoid and myeloid cell distributions between experimental replicates using UMAP plots. (D) Expected and observed Local Inverse Simpson’s Index (LISI) measuring the degree of mixing among datasets. The LISI score ranges from 1 in an unmixed space to 2 in a perfectly mixed space with equal numbers of cells in each dataset. (E) AUCs calculated based on fivefold cross-validation where cells from each cluster are split into training and test datasets, a logistic regression classifier is trained on the training dataset and applied to the test dataset to measure model accuracy for each cluster. Higher AUC values correspond to better cluster discrimination. (F) Comparison of the number of cells detected per cluster in the I/V and CP/CPV datasets. (G) Comparison of the number of genes detected per cluster. (H) UMAP of all CD45+ cells sorted from I/V- and CP/CPV-treated tumor infiltrates, colored by cell cluster based on Louvain clustering. (I) Dot plots of cluster-defining marker genes for cell type annotations (as in H). Dot size represents fraction of cells expressing a gene in each cluster. Dot color represents scaled average expression by gene column.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Quality control and cluster identification of CD45-enriched scRNAseq data. In the I/V model, BALB/c mice were administered 100k CT26 cells and treated when tumors reached a size of 40mm3 with isotype (I) or anti-VISTA (V). In the CPV model, BALB/c mice were administered 100k CT26 cells and treated with anti-CTLA-4 and anti-PD-1 plus isotype (CP) or plus anti-VISTA (CPV) when tumors reached a size of 600mm3. In both models, CD45+ cells were isolated from the TME and analyzed by scRNAseq. (A) Histogram of the number of reads (left) and the number of genes (right) detected in all cells within the I/V dataset. (B) Histogram of the number of reads (left) and the number of genes (right) detected in all cells within the CP/CPV dataset. (C) Visual representation of lymphoid and myeloid cell distributions between experimental replicates using UMAP plots. (D) Expected and observed Local Inverse Simpson’s Index (LISI) measuring the degree of mixing among datasets. The LISI score ranges from 1 in an unmixed space to 2 in a perfectly mixed space with equal numbers of cells in each dataset. (E) AUCs calculated based on fivefold cross-validation where cells from each cluster are split into training and test datasets, a logistic regression classifier is trained on the training dataset and applied to the test dataset to measure model accuracy for each cluster. Higher AUC values correspond to better cluster discrimination. (F) Comparison of the number of cells detected per cluster in the I/V and CP/CPV datasets. (G) Comparison of the number of genes detected per cluster. (H) UMAP of all CD45+ cells sorted from I/V- and CP/CPV-treated tumor infiltrates, colored by cell cluster based on Louvain clustering. (I) Dot plots of cluster-defining marker genes for cell type annotations (as in H). Dot size represents fraction of cells expressing a gene in each cluster. Dot color represents scaled average expression by gene column.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Additional data supporting Figure 3. (A) Pathway enrichment for each cluster described in figure 3. (B) Comparison of myeloid clusters from this study with those identified by [30]. Dots represent the proportion of myeloid clusters described in this study (bottom) in the Gubin et al. myeloid clusters (left). Each row is normalized by row sums. Cluster identity from [30] was obtained from the original publication. (C) Cluster frequencies as a proportion of the myeloid infiltrate in I/V or CP/CPV treatment.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Additional data supporting Figure 3. (A) Pathway enrichment for each cluster described in figure 3. (B) Comparison of myeloid clusters from this study with those identified by [30]. Dots represent the proportion of myeloid clusters described in this study (bottom) in the Gubin et al. myeloid clusters (left). Each row is normalized by row sums. Cluster identity from [30] was obtained from the original publication. (C) Cluster frequencies as a proportion of the myeloid infiltrate in I/V or CP/CPV treatment.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Supplementary Figure S4. Additional data supporting Figure 6. In the I/V model, BALB/c mice were administered 100k CT26 cells and treated when tumors reached a size of 40mm3 with isotype (I) or anti-VISTA (V). In the CPV model, BALB/c mice were administered 100k CT26 cells and treated with anti-CTLA-4 and anti-PD-1 plus isotype (CP) or plus anti-VISTA (CPV) when tumors reached a size of 600mm3. CD45 + (A-C, E) or CD8+ AH1-tetramer+ (D) cells were isolated from the TME and analyzed by scRNAseq. (A) Stacked bar graph showing all lymphoid cluster frequencies as a proportion of the lymphoid infiltrate for I/V and CP/CPV. (B) Stacked bar graph showing NK cluster frequencies as a proportion of the NK infiltrate for I/V and CP/CPV. (C) Stacked bar graph showing CD8+ T cell cluster frequencies as a proportion of the CD8+ T cell infiltrate for I/V and CP/CPV. (D) Mean cluster frequencies as a proportion of CD8+ AH1-tetramer+ T cells in I/V or CP/CPV treatment. (E) Violin plots showing enrichment of a quiescence gene signature in CD8+ T cell clusters in the CD45 + sorted I/V dataset[58]. *P < 0.05, **P < 0.01, ***P < 0.001.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Supplementary Figure S4. Additional data supporting Figure 6. In the I/V model, BALB/c mice were administered 100k CT26 cells and treated when tumors reached a size of 40mm3 with isotype (I) or anti-VISTA (V). In the CPV model, BALB/c mice were administered 100k CT26 cells and treated with anti-CTLA-4 and anti-PD-1 plus isotype (CP) or plus anti-VISTA (CPV) when tumors reached a size of 600mm3. CD45 + (A-C, E) or CD8+ AH1-tetramer+ (D) cells were isolated from the TME and analyzed by scRNAseq. (A) Stacked bar graph showing all lymphoid cluster frequencies as a proportion of the lymphoid infiltrate for I/V and CP/CPV. (B) Stacked bar graph showing NK cluster frequencies as a proportion of the NK infiltrate for I/V and CP/CPV. (C) Stacked bar graph showing CD8+ T cell cluster frequencies as a proportion of the CD8+ T cell infiltrate for I/V and CP/CPV. (D) Mean cluster frequencies as a proportion of CD8+ AH1-tetramer+ T cells in I/V or CP/CPV treatment. (E) Violin plots showing enrichment of a quiescence gene signature in CD8+ T cell clusters in the CD45 + sorted I/V dataset[58]. *P < 0.05, **P < 0.01, ***P < 0.001.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Supplementary Figure S3. Anti-VISTA-induced changes to tumor-infiltrating immune cells in MB49. B6 mice were injected intra-dermally with 100k MB49 cells and treated when tumors reached a size of 100mm3 with isotype (I) or anti-VISTA (V). (A) Macrophage to monocyte ratio as determined by flow cytometry (B) Macrophage (CD45+, CD11b+, Gr1-, F4/80hi) frequency per gram of tumor as determined by flow cytometry. Expression of iNOS (C), MHC-II (D), and CD40 (E), was determined on CD45+, CD11b+, Gr1-, F4/80+ macrophages by flow cytometry. (F) CD40 expression within granulocytes (CD45+, CD11b+, Ly6G+, F4/80-) as determined by flow cytometry. Data are represented as mean ± SD. *P < 0.05.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance
Supplementary Figure S3. Anti-VISTA-induced changes to tumor-infiltrating immune cells in MB49. B6 mice were injected intra-dermally with 100k MB49 cells and treated when tumors reached a size of 100mm3 with isotype (I) or anti-VISTA (V). (A) Macrophage to monocyte ratio as determined by flow cytometry (B) Macrophage (CD45+, CD11b+, Gr1-, F4/80hi) frequency per gram of tumor as determined by flow cytometry. Expression of iNOS (C), MHC-II (D), and CD40 (E), was determined on CD45+, CD11b+, Gr1-, F4/80+ macrophages by flow cytometry. (F) CD40 expression within granulocytes (CD45+, CD11b+, Ly6G+, F4/80-) as determined by flow cytometry. Data are represented as mean ± SD. *P < 0.05.